On this page
Back to topCarlsmed CARL
Carlsmed listed on Nasdaq on 24 Jul 2025 and is not in the S&P 500. It is worth $472 million. Its board has 8 directors, 5 of them independent. 4 other officers are on file.
- Chair and CEO
- Michael Cordonnier
- Listed
- 24 Jul 2025 on Nasdaq
- Headquarters
- Carlsbad, CA
- Market cap
- $472M
- 19 Nov 2026 close
- Price to sales
- 9.3
- Market cap over revenue
Financials
Financial history
Twelve months to 30 Sep 2026, from Carlsmed's quarterly filings.
Quarters since Jun 2024
- Revenue
- $72M
- Up 60% on the year before
- Net income
- $-40M
- -55.8% of revenue
- Free cash flow
- $-35M
- Operating cash flow less capital spending
- P/E
- -
- No profit over the last four quarters
Quarterly results
Each quarter's revenue, net income and free cash flow.
Jun 2024 to Sep 2026
| Quarter | Revenue | Net income |
|---|---|---|
| Sep 2026 | $22M | $-12M |
| Jun 2026 | $19M | $-11M |
| Mar 2026 | $16M | $-9M |
| Dec 2025 | $15M | $-9M |
| Sep 2025 | $13M | $-9M |
| Jun 2025 | $12M | $-7M |
| Mar 2025 | $10M | $-6M |
| Dec 2024 | $9M | $-5M |
| Sep 2024 | $7M | $-8M |
| Jun 2024 | $6M | $-6M |
Carlsmed's market cap since July 2025
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $470M |
| 26 Dec 2025 | $360M |
Download Carlsmed's data as JSON, with the weekly market caps in billions of dollars from 25 Jul 2025.
Board and leadership
Board and officers
Board from the proxy filed 22 Apr 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (8) | |||||
| Michael CordonnierChair; CEO, PresidentNot independent · since 2018 | |||||
| Niall CaseyChief IP OfficerNot independent · since 2018 | |||||
| Robert Mittendorff, M.D., M.B.A.DirectorIndependent · since 2022 · Compensation, Nominating and Corporate GovernanceGeneral Partner and Head of Healthcare, B Capital Group | |||||
| Kevin O'BoyleDirectorIndependent · since 2024 · Audit (chair), CompensationExecutive management professional in the medical device industry | |||||
| Kevin C. OboyleDirector | |||||
| Jonathan D. RootDirectorIndependent · since 2020 · Nominating and Corporate Governance (chair)Managing Member, Presidio Management Group X, LLC and U.S. Venture Partners fundsOther boards: Omada Health and Edgewise Therapeutics | |||||
| Kevin SidowLead Independent DirectorIndependent · since 2020 · Audit, Compensation (chair), Nominating and Corporate GovernanceFormer President and Chief Executive Officer, Moximed, Inc. | |||||
| Philip M. YoungDirectorIndependent · since 2020 · AuditSenior Advisor, U.S. Venture Partners | |||||
| Officers (4) | |||||
| Richard HeppenstallCFO, TreasurerLast filed 30 Sep 2026 | |||||
| Jeffrey BertoliniChief Operating OfficerLast filed 10 Sep 2026 | |||||
| William Scott DurallChief Commercial OfficerLast filed 30 Jan 2026 | |||||
| Jennifer KamocsayChief Legal OfficerLast filed 30 Sep 2026 | |||||
Owners and trading
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers sold $2.7 million of stock in 5 sales and made no open-market purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 3 Nov 2026Sale | Jeffrey BertoliniChief Operating Officer | $11K |
| 30 Oct 2026Sale | Jeffrey BertoliniChief Operating Officer | $4K |
| 5 Oct 2026Sale | Jeffrey BertoliniChief Operating Officer | $11K |
| 30 Sep 2026Sale | Jeffrey BertoliniChief Operating Officer | $3K |
| 2 Mar 2026Sale | Michael CordonnierCEO, President | $2.6M |
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
1 departure and 2 appointments of directors and officers and 1 large insider sale in the last two years.
Insider sales of $1 million or more, and the largest tenth of Carlsmed's insider sales.
Events, newest first
- 24 Sep 2026 Leo Greenstein leftChief Financial Officer, effective 25 Sep 2026
- 24 Sep 2026 Richard Heppenstall appointedChief Financial Officer, effective 28 Sep 2026
- 4 Sep 2026 Jeffrey Bertolini appointedChief Operating Officer, effective 8 Sep 2026
- 2 Mar 2026 Michael Cordonnier sold $2.6MCEO, President
| Date | Event | Filing |
|---|---|---|
| 24 Sep 2026 | Leo Greenstein leftChief Financial Officer, effective 25 Sep 2026 | 8-K |
| 24 Sep 2026 | Richard Heppenstall appointedChief Financial Officer, effective 28 Sep 2026 | 8-K |
| 4 Sep 2026 | Jeffrey Bertolini appointedChief Operating Officer, effective 8 Sep 2026 | 8-K |
| 2 Mar 2026 | Michael Cordonnier sold $2.6MCEO, President | Form 4 |
Not on file: no 13F holdings reported, no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.